Form 4: Director Equity Grants at Tarsus Pharmaceuticals

William J. Link, Ph.D., a director at Tarsus Pharmaceuticals, received stock options and restricted stock units as compensation for his services.

Summary

• William J. Link, Ph.D., a director of Tarsus Pharmaceuticals, Inc., was granted stock options and restricted stock units (RSUs) on June 25, 2026.
• The stock option grant is for 3,837 shares with an exercise price of $64.34, expiring on June 24, 2036.
• This option is an annual grant for his role as a non-employee director and vests in full one year from the grant date, contingent on continued service.
• Additionally, Dr. Link received 2,417 RSUs, each representing a contingent right to one share of common stock, also granted for his director services.
• These specific RSUs vest in full one year from the grant date, subject to continued service.
• A separate grant of 806 RSUs was also awarded, vesting in equal installments on September 15, 2026, December 15, 2026, March 15, 2027, and June 15, 2027, also contingent on continued service.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it represents routine director compensation and does not provide new financial performance data or strategic shifts.

Positives

• Director compensation through equity awards aligns incentives between management and shareholders.
• The grants of stock options and RSUs indicate continued confidence in the company's long-term prospects by its board.
• Vesting schedules tied to continued service encourage director retention and commitment.

Negatives

• The exercise price of the stock option ($64.34) suggests a high valuation expectation for the company's stock.
• The vesting schedule for some RSUs extends over a year, meaning immediate impact on share price is unlikely.

Risks

• The value of the equity awards is subject to market fluctuations and the company's future performance.
• If Dr. Link's continuous service is not maintained, the equity awards may not fully vest.

Future Outlook

The filing does not contain forward-looking statements or guidance. It solely reports on equity grants made to a director.

Industry Context

StockSavvy.ai notes that the issuance of stock options and RSUs to directors is a standard practice in the biopharmaceutical industry to attract and retain experienced leadership and align their interests with shareholders. The specific grant sizes and exercise prices are typical for companies at Tarsus Pharmaceuticals' stage, reflecting compensation structures designed to incentivize long-term value creation.

Related Party Transactions

• The grant of stock options and restricted stock units to director William J. Link, Ph.D. constitutes a related party transaction.

Stakeholder Impact

• Shareholders: The equity awards align director incentives with shareholder value creation, but the dilutive effect of future share issuances upon vesting should be considered.
• Employees: This filing does not directly impact employees, but it reflects the company's compensation strategy for its board.
• Management: The filing is routine and does not directly impact executive management's day-to-day operations.

Next Steps

• William J. Link, Ph.D. will continue his service as a director.
• The granted stock options and RSUs will vest according to their respective schedules, contingent on continued service.

Key Dates

Keywords

Tarsus Pharmaceuticals, Form 4, SEC Filing, Director Compensation, Stock Options, Restricted Stock Units, Equity Awards, William J. Link, Insider Trading, Beneficial Ownership